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Pneumocoques (CNRP), AP-HP HEGP, Paris, 3) Institut de Veille Sanitaire (InVS), Saint Maurice and 4) CHU Limoges, UFRCB, Limoges, FranceAbstractStreptococcus pneumoniae is an important cause of acute otitis media (AOM). The aim of this study was to evaluate trends in antibiotic
resistance and circulating serotypes of pneumococci isolated from middle ear ﬂuid of French children with AOM during the period
2001–2011, before and after the introduction of the PCV-7 (2003) and PCV-13 (2010) vaccines. Between 2001 and 2011 the French
pneumococcal surveillance network analysed the antibiotic susceptibility of 6683 S. pneumoniae isolated from children with AOM, of
which 1569 were serotyped. We observed a signiﬁcant overall increase in antibiotic susceptibility. Respective resistance (I+R) rates in
2001 and 2011 were 76.9% and 57.3% for penicillin, 43.0% and 29.8% for amoxicillin, and 28.6% and 13.0% for cefotaxime. We also
found a marked reduction in vaccine serotypes after PCV-7 implementation, from 63.0% in 2001 to 13.2% in 2011, while the incidence of
the additional six serotypes included in PCV-13 increased during the same period, with a particularly high proportion of 19A isolates.
The proportion of some non-PCV-13 serotypes also increased between 2001 and 2011, especially 15A and 23A. Before PCV-7
implementation, most (70.8%) penicillin non-susceptible pneumococci belonged to PCV-7 serotypes, whereas in 2011, 56.8% of penicillin
non-susceptible pneumococci belonged to serotype 19A. Between 2001 and 2011, antibiotic resistance among pneumococci responsible
for AOM in France fell markedly, and PCV-7 serotypes were replaced by non-PCV-7 serotypes, especially 19A. We are continuing to
assess the impact of PCV-13, introduced in France in 2010, on pneumococcal serotype circulation and antibiotic resistance.
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E-mail: philippe.lanotte@univ-tours.frIntroductionAcute otitis media (AOM) is the most common bacterial
infection in childhood and one of the most frequent indicationsClinical Microbiology and Infection © 2014 European Society of Cfor antibiotic treatment of young children [1]. Among the
pathogens involved in this infection, Streptococcus pneumoniae is
the most frequently isolated, together with Haemophilus inﬂu-
enzae [2]. In recent decades the emergence and spread of
penicillin non-susceptible pneumococci (PNSP) has limited the
therapeutic options in AOM, as penicillin non-susceptibility is
associated with reduced activity of other oral β-lactams [3–5].
In France, a steady increase in the percentage of PNSP isolates
in both invasive and non-invasive infections has been observed
since the 1990s, reaching 55.4% overall in 2001 and 77% among
paediatric AOM isolates [6]. In 2001 the French national healthClin Microbiol Infect 2015; 21: 35–42
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inappropriate antibiotic use among outpatients [6]. The hep-
tavalent pneumococcal conjugate vaccine (PCV-7) was recom-
mended for at-risk children under 2 years of age in 2002, and
for all children in 2006 [7]. PCV-7 vaccine coverage increased
slowly: at least one dose was received by 62% of children under
2 years old in 2006, rising to 69% in 2007, 85% in 2008 and 90%
in 2009 [7]. PCV-13 gradually replaced PCV-7 over a 3-month
period between June and early September 2010 [8]. In 2011,
the full primary vaccination coverage rate was 91.7% among 9-
month-old infants [Public Health Institute unpublished data,
available at http://www.invs.sante.fr/Dossiers-thematiques/
Maladies-infectieuses/Maladies-a-prevention-vaccinale/
Couverture-vaccinale/Donnees/Pneumocoque].
The aim of this study was to evaluate, through the French
pneumococcal surveillance network (Observatoires Régionaux
du Pneumocoque, Centre National de Référence des Pneu-
mocoques, Institut de Veille Sanitaire), changes in antibiotic
resistance and circulating serotypes of S. pneumoniae isolated
from middle ear ﬂuid of children (0–16 years) with AOM over
an 11-year period (2001–2011) following the introduction of
PCV-7 and PCV-13.Materials and MethodsData and strain collection
Surveys were conducted every 2 years from January 2001 to
December 2011 by the French pneumococcal network, which
includes 396 public (75%) and private (25%) laboratories in 23
regions, as previously described [6]. All isolates from middle ear
ﬂuid of children aged 0–16 years were included in the study.
Only one strain was considered per AOM episode and per child.
Susceptibility testing
Minimal inhibitory concentrations (MICs) of penicillin G, amox-
icillin and cefotaxime were determined with the agar dilution
method according to the guidelines of the Comité de l’Anti-
biogramme de la Société Française de Microbiologie (www.sfm.
org). Three quality-control strains (R6 (WT), ATCC49619 andTABLE 1. Resistance of pneumococcal isolates from children’s mid
2001 (n [ 1694) 2003 (n [ 1378) 2005 (n [ 1159)
PEN I+R, n (%) 1302 (76.9) 959 (69.6) 736 (63.5)
AMX I+R, n (%) 729 (43.0) 572 (41.5) 405 (34.9)
CTX I+R, n (%) 485 (28.6) 369 (26.8) 259 (22.3)
ERYa I+R, n (%) 1303 (77.6) 1016 (74.1) 708 (61.9)
SXTb I+R, n (%) 862 (53.8) 572 (47.7) 386 (39.3)
Abbreviations: AMX, amoxicillin; CTX, cefotaxime; ERY, erythromycin; PEN, penicillin G; SX
Note: p values are from a χ2-test for trends
aFor erythromycin (ERY), the number and percentage of I+R isolates were calculated for 16
bFor cotrimoxazole (SXT), the number and percentage of I+R isolates were calculated for 1
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectCNRP32475) provided by the French National Reference
Centre for Pneumococci (CNRP) were included. Erythromycin
and cotrimoxazole susceptibility was determined using the disk
diffusion method, the VITEK2® kit or the ATB-Pneumo® kit. The
results were interpreted according to 2009 French guidelines,
with the following breakpoints: 0.064–2 mg/L for penicillin, and
0.5–2 mg/L for amoxicillin and cefotaxime. PNSP were deﬁned
as strains with a penicillin MIC >0.064 mg/L.
Serotyping
A subset of isolates was selected for serotyping by random
systematic sampling. Serotyping was performed by the National
Pneumococcal Reference Centre, using the capsular swelling
method with commercial antisera (Statens Serum Institute,
Copenhagen, Denmark). The panel of antisera covered the 92
known serotypes.
Statistical analysis
Data were monitored and validated with CAPTURE SYSTEM soft-
ware. SAS software (version 9.1.3., SAS Institute, Cary, NC,
USA) was used for statistical analysis, using the chi-square test
for trends. Values of p < 0.05 were considered to denote sig-
niﬁcant differences.ResultsWe studied 6683 isolates recovered from middle ear ﬂuid of
6683 children with AOM. The annual number of pneumococcal
isolates declined gradually during the study period, from 1694 in
2001 to 1378 in 2003, 1159 in 2005, 998 in 2007, 922 in 2009
and 560 in 2011. The children’s mean age ± SD was 1.9 ± 2.0
years. A total of 2189 isolates (32.8%) were recovered from
children less than 12 months old, and 2314 (34.6%) from chil-
dren between 1 and 2 years old.
Antimicrobial resistance
Trends in resistance (I+R) to penicillin, amoxicillin, cefotaxime,
erythromycin and cotrimoxazole among the 6683 isolates are
shown in Table 1. A signiﬁcant decrease in overall antibioticdle ear ﬂuid to ﬁve antibiotics; France 2001–2011
2007 (n [ 998) 2009 (n [ 922) 2011 (n [ 560) p
604 (60.5) 581 (63.0) 321 (57.3) <10−5
298 (29.9) 338 (36.7) 167 (29.8) <10−5
164 (16.4) 192 (20.8) 73 (13.0) <10−5
585 (59.3) 541 (58.7) 310 (55.4) <10−5
306 (31.7) 419 (45.4) 130 (23.2) <10−5
T, cotrimoxazole.
80, 1370, 1143 and 986 isolates in 2001, 2003, 2005 and 2007, respectively
602, 1200, 981 and 968 isolates in 2001, 2003, 2005 and 2007, respectively.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 35–42
CMI Kempf et al. Pneumococcal epidemiology in AOM, France 37resistance (% of I+R) was observed (p < 10−5); 76.9% of the
strains were PNSP in 2001 compared with 57.3% in 2011.
Concerning the two other β-lactams tested, 43.0% and 28.6%
of the strains were non-susceptible (I+R) to amoxicillin and
cefotaxime, respectively, in 2001, compared with 29.8% and
13.0% in 2011. The largest decreases concerned cotrimoxazole
(53.8% in 2001 versus 23.2% in 2011) and erythromycin (77.6%
in 2001 versus 55.4% in 2011).
The most common resistance phenotypes are shown in
Table 2. In 2001, 15.1% of the isolates were susceptible to all
the antibiotics tested, compared with 34.5% in 2011. No
pneumococcal strains susceptible to penicillin but exhibiting
reduced susceptibility to amoxicillin or cefotaxime were found.
Multidrug resistance, deﬁned as resistance to at least three
antibiotic classes [9], was found in 60.3% of isolates in 2001,
compared with 31.8% in 2011. It is particularly noteworthy that
the proportion of strains resistant to
penicillin + amoxicillin + erythromycin + cotrimoxazole fell
from 31.7% in 2001 to 7.3% in 2011. Most multidrug-resistant
strains showed diminished susceptibility to β-lactams and
resistance to macrolides.
The resistance was explored as a function of patients’ age.
The proportion of PNSP isolated from AOM in children under
12 months of age was near 30%, without major variation be-
tween the studied years. The proportion of PNSP reached 70%
for those aged between 13 and 24 months. For children from
the age of 24 months the PNSP rate was almost 50%. In all the
cases, there were no major variations between the studied
years (data not shown).
Serotype distribution
A total of 1569 S. pneumoniae isolates (23.5%) were serotyped:
341 in 2001, 367 in 2003, 200 in 2005, 308 in 2007, 201 in
2009, and 152 in 2011. Between 2001 and 2011, we observed aTABLE 2. Most common resistance phenotypes of Streptococcus
2001–2011
I+R phenotypes 2001 (n [ 1598) 2003 (n [ 1195) 2005 (n [ 98
No resistance marker 241 (15.1) 248 (20.8) 267 (27.2)
PEN 36 (2.3) 21 (1.8) 33 (3.4)
AMX 0 (0.0) 0 (0.0) 0 (0.0)
ERY 89 (5.6) 89 (7.4) 53 (5.4)
SXT 12 (0.8) 17 (1.4) 20 (2.0)
PEN+AMX 8 (0.5) 6 (0.5) 17 (1.7)
PEN+ERY 211 (13.2) 135 (11.3) 116 (11.8)
PEN+SXT 15 (0.9) 6 (0.5) 13 (1.3)
AMX+ERY 0 (0.0) 0 (0.0) 0 (0.0)
AMX+SXT 0 (0.0) 0 (0.0) 0 (0.0)
ERY+SXT 21 (1.3) 19 (1.6) 20 (2.0)
PEN+AMX+ERY 145 (9.1) 124 (10.4) 109 (11.1)
PEN+AMX+SXT 34 (2.1) 19 (1.6) 23 (2.3)
PEN+ERY+SXT 278 (17.4) 171 (14.3) 116 (11.8)
AMX+ERY+SXT 0 (0.0) 0 (0.0) 0 (0.0)
PEN+AMX+ERY+SXT 507 (31.7) 337 (28.2) 193 (19.7)
Abbreviations: AMX, amoxicillin; ERY, erythromycin; PEN, penicillin G; SXT, cotrimoxazole
Note: Data are given as n (%); p values are from a χ2-test for trends
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiolosigniﬁcant decline in PCV-7 serotypes (63.0% vs 13.2%,
p < 0.05) (Fig. 1). The prevalence of serotype 19F fell from
16.1% to 9.9%; serotype 14 from 19.1% to 1.3%; serotype 6B
from 10.6% to 0.0%; serotype 23F from 10.9% to 1.3%; sero-
type 9V from 4.7% to 0.0% (p < 0.01); serotype 18C from 1.2%
to 0.7%, and serotype 4 from 0.6% to 0.0%. The prevalence of
the six additional serotypes covered by PCV-13 rose between
2001 (27.9%) and 2009 (70.6%, p < 0.05), then fell in 2011
(49.3%) (p < 0.05). Serotype 19A represented 19.6% of isolates
in 2001 and 51.2% in 2009, falling to 38.2% in 2011. Finally,
some non-PCV-13 serotypes became more prevalent between
2001 and 2011, particularly serotype 15A (2001: 0.3%; 2011:
6.6%) and serotype 23A (2001: 0.6%; 2011: 3.9%).
Trends in PNSP serotypes
In 2001, before the introduction of PCV-7 in France, most
PNSP (70.8%) belonged to PCV-7 vaccine serotypes (Fig. 2).
The proportion of PNSP declined after 2003, mainly as the
result of a fall in PCV-7 serotypes: 66.8% of PNSP belonged to
PCV-7 serotypes in 2003, compared with 52.6% in 2005, 26.3%
in 2007, 8.9% in 2009, and 17.9% in 2011. Among non-PCV-7
serotypes, serotype 19A was most prevalent, rising steadily
until 2009, when it represented a large majority of PNSP: 23.6%
in 2001, 29.0% in 2003, 37.1% in 2005, 62.5% in 2007, 76.0% in
2009, and 56.8% in 2011. Concerning the other non-vaccine
serotypes, isolates belonging to serotypes 15A and 35B were
the most resistant to penicillin G.DiscussionThis is the ﬁrst nationwide long-term follow-up study of trends
in S. pneumoniae resistance and serotype distribution in French
children with AOM. As expected, routine paediatricpneumoniae isolates from children’s middle ear ﬂuid; France
0) 2007 (n [ 985) 2009 (n [ 922) 2011(n [ 560) p
316 (32.1) 293 (31.8) 193 (34.5) <10−5
26 (2.6) 23 (2.5) 22 (3.9) <0.05
0 (0.0) 0 (0.0) 0 (0.0) NS
42 (4.3) 19 (2.1) 29 (5.2) <0.001
25 (2.5) 23 (2.5) 12 (2.1) <0.001
15 (1.5) 20 (2.2) 14 (2.5) <10−5
138 (14.0) 90 (9.8) 102 (18.2) NS
12 (1.2) 15 (1.6) 5 (0.9) NS
0 (0.0) 0 (0.0) 0 (0.0) NS
0 (0.0) 0 (0.0) 0 (0.0) NS
9 (0.9) 6 (0.7) 5 (0.9) NS
137 (13.9) 106 (11.5) 108 (19.3) <10−5
6 (0.6) 6 (0.7) 4 (0.7) <0.001
126 (12.8) 114 (12.4) 25 (4.5) <10−5
0 (0.0) 0 (0.0) 0 (0.0) NS
133 (13.5) 206 (22.3) 41 (7.3) <10−5
.
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FIG. 1. Trends in Streptococcus pneumoniae serotypes isolated from middle ear ﬂuid of French children with acute otitis media between 2001 and 2011.
38 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIimmunization programmes with the PCV-7 vaccine, beginning in
2003, led to a decline in the proportion of cases due to PCV-7
serotypes. Similar results have been obtained in other countries
such as the USA, where PCV-7 was licensed in 2000 and where
several studies of AOM have shown a decline in PCV-7 sero-
types in favour of non-vaccine serotypes [10–12]. In a recent
Spanish study, Alonso et al. also observed that the prevalence of
PCV-7 serotypes causing AOM declined sharply after the
introduction of PCV-7 in 2001, from 62.4% in the 1999–2001
pre-vaccination period to 2.2% in the 2008–2010 late vacci-
nation period [13]. Likewise, a decline of S. pneumoniae isola-
tion has been observed in children with chronic sinusitis, as
described by Olarte et al., with a substantial reduction of PCV-
13 serotypes, predominantly serotype 19A [14].
According to Rodgers et al. [2], the most common serotypes
causing AOM worldwide in the 1970–2008 period were 6A,
6B, 14, 19A, 19F, and 23F. In our study, serotype 6A repre-
sented only 0–3% of all isolates. However, we found that
serotype 3, which was not mentioned by Rodgers et al., became
more prevalent between 2001 and 2011 (4.7% and 8.6%,
respectively). Serotype 19A became the leading non-PCV-7
serotype, accounting for more than 50% of isolates in 2009.
Our results are consistent with those of Cohen et al. [7],
who studied nasopharyngeal samples from French children with
AOM before and after PCV-7 implementation. These authors
found a marked reduction in vaccine serotype carriage after
PCV-7 implementation. They also observed an increase in non-
PCV-7 serotypes (notably 19A, the prevalence of which rose
from 6% to 22%), and also in other non-vaccine serotypes such
as 15A, 23A, 35B and 23B. Recently, Cohen et al. [8] showedClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthat in French children with AOM, the carriage of serotypes
19A and 7F was signiﬁcantly lower in PCV-13-vaccinated pa-
tients than in those vaccinated only with PCV-7. These obser-
vations were further conﬁrmed by Hau et al. [15], who
reported that PCV-13 introduction in France led to a further
reduction in nasopharyngeal carriage of the six additional se-
rotypes included in this vaccine. In our study, serotype 19A
increased gradually from 2001 to 2009 but declined markedly in
2011 (51.2% in 2009 versus 38.2% in 2011), probably due to the
introduction of PCV-13 in 2010. Further studies are needed to
conﬁrm this relationship, and also the decline in the other
additional serotypes included in PCV-13.
The relationship between antibiotic resistance and the
pneumococcal serotype is well known [16]. Before PCV-7
introduction, the most common serotypes carried by children
with AOM, and also the most commonly resistant serotypes,
were the vaccine serotypes 6B, 9V, 14, 19F and 23F and the
non-vaccine serotypes 6A and 19A [16]. The introduction of
PCV-7 was associated with a decline in vaccine serotypes, and
hence in antibiotic resistance. We found that the decline in
PNSP over the study period coincided with an increase in the
number of isolates susceptible to all the antibiotics tested
(15.1% in 2011 versus 34.5% in 2011). From 2001 to 2005,
most PNSP isolates belonged to PCV-7 serotypes, and the
decline in these strains accounted for the decrease in antibiotic
resistance. Most isolates belonging to serotype 19A, a non-
PCV-7 serotype, were resistant to antibiotics, with a PNSP
rate close to 90%. This decline in antibiotic resistance is ex-
pected to continue, as a result of the decline in serotype 19A,
which is covered by PCV-13. Besides, a decrease in the level ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 35–42
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FIG. 2. Trends in the serotype distribution of Streptococcus pneumoniae isolated from middle ear ﬂuid of French children with acute otitis media,
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CMI Kempf et al. Pneumococcal epidemiology in AOM, France 41multidrug-resistant isolates has been observed (31.7% in 2001
to 7.3% in 2011), probably related to an association of multiple
mechanisms of resistance in certain serotypes.
Levels of antibiotic resistance are directly proportional to
antibiotic consumption in the community [16,17]. Multivariate
analysis of data from 21 European countries in 2000–2005
demonstrated signiﬁcant positive associations (p  0.01) be-
tween PNSP rates and levels of penicillin consumption [18]. In
France, overall community antimicrobial consumption fell from
33.0 deﬁned daily doses per 1000 inhabitants in 2001 to 27.1 in
2004; broad-spectrum penicillin consumption fell by 20% and
macrolide consumption by 39% [19]. Since then, a slight in-
crease has been observed, reaching 28.7 deﬁned daily doses per
1000 inhabitants in 2011 (data from the ANSM 2013 report
http://ansm.sante.fr).
The number of S. pneumoniae strains recovered from middle
ear ﬂuid of children diagnosed with AOM fell from 1694 in
2001 to only 560 in 2011. This was probably due to PCV-7
vaccination, although a change in medical practices, and espe-
cially in the indications of tympanocentesis, cannot be ruled out.
In France, tympanocentesis and bacteriological analysis are not
usually performed at the ﬁrst medical examination for AOM but
are reserved for treatment failure, relapse or recurrence.
However, even if practices did change, the decline in resistant
pneumococci recovered from children with AOM remains
remarkable.
In conclusion, the frequency of non-susceptible pneumo-
cocci isolated from middle ear ﬂuid of children with AOM fell
signiﬁcantly in France between 2001 and 2011. This was mainly
due to a decline in isolates belonging to PCV-7 serotypes, most
of which were resistant to antibiotics. Implementation of PCV-
7, followed in 2010 by PCV-13, was associated with a dramatic
change in the epidemiology of pneumococcal AOM in France.Transparency DeclarationThe authors declare that they have no conﬂicts of interest.AcknowledgementsWe thank the participating laboratories for their active
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